Cite
Basile V, Puglisi S, Altieri B, et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021;11(4)doi: 10.3390/jpm11040269.
Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F., Beuschlein, F., Quinkler, M., Calabrese, A., Perotti, P., Berchialla, P., Dischinger, U., Megerle, F., Baudin, E., Bourdeau, I., Lacroix, A., Loli, P., Berruti, A., Kastelan, D., Haak, H. R., Fassnacht, M., & Terzolo, M. (2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of personalized medicine, 11(4), . https://doi.org/10.3390/jpm11040269
Basile, Vittoria, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of personalized medicine vol. 11,4 (2021). doi: https://doi.org/10.3390/jpm11040269
Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021 Apr 04;11(4). doi: 10.3390/jpm11040269. PMID: 33916613; PMCID: PMC8066814.
Copy
Download .nbib